Tissue fibrosis results, in part, from an interaction between growth regulatory molecules released by mononuclear phagocytes and fibroblasts. In the chronic interstitial lung disorders, alveolar macrophages, the mononuclear phagocytes of the lung, are known to spontaneously release two growth factors for fibroblasts, fibronectin and alveolar macrophage-derived growth factor (AMDGF) that together stimulate nonreplicating lung fibroblasts to divide. In addition to these two primary growth promoting signals, alveolar macrophages are able to release other mediators that may have a potential role in modulating lung fibroblast replication in response to these primary signals, including interferon y (IFNy), prostaglandin E2 (PGE2), and interleukin 1 (IL-1).
Introduction
Mononuclear phagocytes are thought to play a central role in the pathogenesis oftissue fibrosis by releasing growth regulatory molecules for fibroblasts (1) (2) (3) (4) (5) (6) (7) (8) (9) . This concept has received strong experimental support in the fibrotic process of the chronic in-terstitial lung disorders. These disorders are invariably associated with alveolar inflammation in which activated alveolar macrophages, the mononuclear phagocytes of the lung, comprise an important component (10) (11) (12) (13) . Within any region ofthe alveolar wall, an accumulation of alveolar macrophages precedes the increase in fibroblast number that characterizes the fibrotic process (12, 13) . Furthermore, alveolar macrophages from most patients with interstitial fibrosis spontaneously release two primary growth factors for lung fibroblasts, fibronectin and alveolar macrophage-derived growth factor (AMDGF),' that, together with transferrin, can stimulate fibroblasts to proliferate, thus leading to an expansion of fibroblast numbers within the alveolar structures (3) (4) (5) . Specifically, fibronectin, a 440,000-D glycoprotein, acts as a "competence factor" that delivers a growth promoting signal to nonreplicating lung fibroblasts early in the GI phase of the cell cycle, making them responsive to the subsequent presence of a second growth promoting signal later in GI (progression factor) (4) . AMDGF, an 18,000-D peptide, delivers a progression signal later in GI permitting lung fibroblasts previously exposed to a competence signal (e.g., fibronectin) to replicate (2) . In the context ofthese observations, alveolar macrophage-released fibronectin and AMDGF are thought to be the primary signals that drive fibroblasts to expand in numbers in the interstitial lung disorders.
In addition to the primary signals of fibronectin and AMDGF, there are several well characterized alveolar macrophage mediators that may also play a role in modulating lung fibroblast replication. These include interferon y (IFNy), pros--taglandin E2 (PGE2), and interleukin 1 (IL-1). IFNy, a 25,000-D glycoprotein, is spontaneously released by alveolar macrophages in several interstitial lung disorders (14, 15). Besides its multiplicity of activities in modulating immune processes (16) , IFNy is generally known to down-regulate cell replication (17) , although its influence on the proliferation of diploid human fibroblasts in defined conditions is unknown. PGE2, a 352-D cyclooxygenase metabolite of arachidonic acid, is spontaneously released by normal alveolar macrophages. PGE2 is known to suppress serum growth factor-driven proliferation ofdiploid human fibroblasts (18, 19) . IL-1, a 12,000-15,000-D protein, can be produced by alveolar macrophages, although to a far less extent than by blood monocytes (20, 21) . Observations by Schmidt et al. (6) indicated that IL-I will augment serum stimulated diploid human fibroblast replication. Consistent with this finding, Estes and co-workers (22) have shown that IL-1 will augment 3T3 cell replication in plasma containing suboptimal concentrations of platelet-derived growth factor (PDGF). Thus, while fibronectin and AMDGF are sufficient to drive fibroblasts to proliferate, it is reasonable to hypothesize that the primary 1 . Abbreviations used in this paper: AMDGF, alveolar macrophage-derived growth factor; DME, Dulbecco's modified Eagle's medium; FGF, fibroblast growth factor; IFNy, interferon 'y; IL-1, interleukin 1; PDGF, platelet-derived growth factor; PGE2, prostaglandin E2. 700 signals delivered by fibronectin and AMDGF may be modulated by these other macrophage products.
In this regard, the purpose of the present study was to determine the potential biological importance of IFN-y, PGE2, and IL-1 to the process of lung fibroblast replication in response to fibronectin and AMDGF in serum-free defined conditions. The data indicate that PGE2 is able to inhibit lung fibroblast replication in response to fibronectin and AMDGF, while IFN-y has no effect. In contrast, while IL-1 is unable to provide a primary growth signal to nonreplicating fibroblasts, it is able to modestly augment fibroblast replication in response to fibronectin and AMDGF.
Methods

Preparation ofmediators
Fibronectin. Fibronectin was purified from plasma in two ways: (a) gelatin-sepharose affinity chromatography as described by Engvall and Ruoslahti (23) Further purification of AMDGF was attempted using a variety of techniques, but due to limited quantities of crude factor and its apparent lability, significant amounts of further purified material were not available for use in these studies. However, additional characteristics of AMDGF were determined. These characteristics included: activity did not bind to cation exchange resins at neutral pH; activity lost during isoelectric focusing (unstable in ampholines), hydrophobic chromatography, and polyacrylamide gel electrophoresis; activity destroyed by boiling and trypsinization; and activity not lipid soluble. AMDGF was identical biologically and biochemically to that previously described (2-4). Interleukin 1. IL-I was prepared from supernates of LPS-stimulated alveolar macrophages (pooled supernates from 5 X 108 macrophages from eight patients with interstitial lung disorders) and blood monocytes (109 from a single donor leukophoresis) by sequential anion exchange and gel filtration chromatography followed by preparative isoelectric focusing as previously described (21). Monocyte and macrophage IL-1 were biochemically and biologically indistinguishable.
Platelet-derived growth factor (PDGF). PDGF was partially purified from human platelets by sequential cation exchange, gel filtration, and preparative isoelectric focusing as described by Vogel et al. (26) .
Other (27) . According to this concept, there are at least two classes of growth factors for fibroblasts. Competence factors (e.g., PDGF, FGF, and fibronectin) act early in GI, enabling an appropriate target cell to respond later in GI to the subsequent presence of progression factors (e.g., insulin, insulin-like growth factors, and AMDGF). Both a competence and progression factor are required for optimal fibroblast replication. This information forms the basis for a growth assay in which none, one, or both classes of factors are present in the fibroblast culture with a test factor.
All studies of fibroblast replication were performed using human lung fibroblasts (HFL-1; American Type Culture Collection CCL 153) maintained in DME plus 10% calf serum (MA Bioproducts) in an atmosphere of 90% air, 10% C02, and used before the 25th population doubling. Unless specifically noted, all fibroblast growth assays were performed in serum-free defined medium containing 1 mg/ml albumin (Sigma Chemical Co.), and 10 ,g/ml saturated transferrin (Collaborative Research, Inc.). This culture system permitted study of the effect ofeach growth factor on fibroblast replication without the complexity introduced by the numerous growth regulatory molecules in serum.
Growth augmentation. In each instance, growth augmentation was assessed by determining cell number. In some experiments, results were corroborated using autoradiography of [3Hjthymidine incorporation into DNA carried out as previously described (2) . Two separate strategies were employed to detect growth promoting effects. The first was designed to assess the ability of a growth factor to signal nonreplicating cells to enter the cell cycle, and the second to examine the ability of a factor to increase replication of cells already signalled to divide.
(a) To assess the ability of a growth factor to signal nonreplicating fibroblasts (GO/GI, referred to as "GI ," phase of the cell cycle) to divide, the cells were cultured with a test factor alone, or in combination with defined growth factors, either a known competence factor or a known progression factor, as previously described (2) . Nonreplicating fibroblasts were prepared by seeding 35 x I03 fibroblasts/35-mm dish (Falcon Labware, Becton-Dickinson & Co., Oxnard, CA) in 2 ml DME, 0.4% calf serum (for cell counts), or at an equivalent density in eight-chamber slides (Lab-Tek, Miles Scientific, Div. of Miles Laboratories, Inc., Napersville, IL) in 0.4 ml of the same medium (for autoradiography). For both cell count and autoradiographic assays, after 3 d, the cells were rinsed three times with assay medium and cultured (37°C, 24 h) in that same medium. The resultant nonreplicating fibroblasts (<6% labeled nuclei/24 h) were cultivated with the various growth factors and the growth response was assessed.
(b) To assess the ability of a factor to augment replication in cells that were signaled to divide, nonreplicating fibroblasts were signaled to traverse the cell cycle either by the complete set of growth promoting signals present in serum or by defined growth factors (both a competence and progression factor). These growth factor-signaled cells were cultured with the test factor for several days with cell number determined each day. Growth factor-signaled cells cultured without the test factor served as a control.
Growth inhibition. The general approach used was to incubate noncycling cells with the putative inhibitor concomitant with the addition of the growth promoting signals. Growth inhibition was assessed by determining cell number as described above.
Ability ofIFNy to modulate lungfibroblast replication induced by defined growth factors Because of its apparent ability to augment replication in some cells (e.g., T lymphocytes) (28) and to inhibit replication in most cells (e.g., several tumor lines) (17), IFN-y was evaluated for its ability to either augment or inhibit lung fibroblast replication.
Augmentation. To assess the ability of IFNy to act as a primary growth promoting signal for lung fibroblast replication, cells were cultured with IFNy in the presence ofeither a known competence or progression factor and the resultant increase in cell number determined. In the test for progression activity, nonreplicating fibroblasts were cultured with varying concentrations ofIFN'y (both recombinant and nonrecombinant) plus a competence factor (PDGF, 0.5 U/ml; FGF, 25 ng/ml; or fibronectin, 1.0 Ag/ml) with cell number determined after 72 h using an electronic particle counter (Coulter ZBI; Coulter Electronics, Inc., Hialeah, FL). In the test for competence activity, nonreplicating fibroblasts were similarly cultured with IFNy except in this case with a progression factor (insulin, 25 ,gg/ml) or AMDGF (5 ng/ml), with cell number determined after 72 h. As a positive control, fibroblasts were cultured with a known competence factor together with a known progression factor.
To determine whether IFNy could augment fibroblast replication in cells stimulated to divide by defined growth factors, fibroblasts were cultured with IFN~yin addition to both a competence and progression factor. This was accomplished by adding varying amounts of IFNy and midrange concentrations of a competence factor (fibronectin, 1.0 gg/ml or FGF, 25 ng/ml) plus a progression factor (AMDGF, 5 ng/ml or insulin, 25 gg/ml) to nonreplicating fibroblasts. Cultures were continued 5 d with cell counts performed daily.
Inhibition. The ability of IFNy to inhibit fibroblast replication was assessed by culturing fibroblasts with IFNy concomitant with a stimulus to divide. To accomplish this, nonreplicating fibroblasts were signaled to divide by optimal concentrations of a competence factor (fibronectin, 2.0 ,ug/ml or FGF, 50 ng/ml) plus a progression factor (AMDGF, 10 ng/ ml or insulin, 50 ,g/ml). Varying amounts of IFN-y (both recombinant and nonrecombinant) were added at the time of addition of the growth factors with cell number determined daily for 5 d.
Ability ofPGE2 to inhibit fibroblast replication induced by defined growth factors POE2 inhibition of fibroblast replication was examined by culturing fibroblasts with PGE2 concurrent with the addition of fibronectin plus AMDGF as described above for IFNy, except that varying amounts of PGE2 (1, 10, 50, and 100 ng/ml) were added at the time of addition of the growth factors with cell number determined daily for 3 d.
Ability ofIL-1 to augmentfibroblast replication
To confirm that, similar to skin fibroblasts, lung fibroblast replication in response to serum could be augmented by IL-l, lung fibroblasts were cultured with serum and varying doses of IL-l (quantified as previously described) with cell counts performed daily for 5 d.
To determine whether IL-I could augment fibroblast replication in cells stimulated to divide by defined growth factors in serum-free conditions, fibroblasts were cultured with IL-l in addition to both a competence and progression factor. This was accomplished by adding varying amounts of IL-I (1-100 U/ml) and mid-range concentrations of a competence factor (FGF, 25 ng/ml; or fibronectin, 1.0 gg/ml) plus a progression factor (AMDGF, 5 ng/ml or insulin, 25 ug/ml) to nonreplicating fibroblasts. Cultures were continued 5 d with cell counts performed daily.
To examine the ability ofIL-I to act as a primary growth promoting signal for lung fibroblast replication, we cultured cells with IL-l in the presence of either a known competence or progression factor and determined the resultant increase in cell number as described above for IFNy. In the test for progression activity, nonreplicating fibroblasts were cultured with optimal concentrations ofIL-1 (100 U/ml) plus a competence factor, and in the test for competence activity, nonreplicating fibroblasts were similarly cultured with IL-l except in this case with a progression factor. Cell number was determined after 72 h. As a positive control, fibroblasts were cultured with a known competence factor together with a known progression factor.
To determine the temporal pattern of the IL-1 augmentation of fibroblast replication, fibroblasts were provided with both a competence and progression factor with IL-I added subsequently as a function of time. This was accomplished by culturing nonreplicating fibroblasts with both a competence and progression factor (fibronectin, 1.0 Ag/ml + AMDGF, 5 ng/ml or FGF, 25 ng/ml + insulin, 25 jig/ml) at the initiation ofthe experiment ( After preliminary studies showed that the action of IL-l to augment growth was only within 4-6 h after the addition of the primary growth signal(s) (i.e., entirely within the G0 phase ofthe cell cycle), synchronized cells were assessed to define the interval in GI when IL-I acted. Cells synchronized in M phase by mitotic detachment (confirmed by flow cytometric determination of DNA content using mithramycin as previously described [29] ) were seeded on slides in medium supplemented with either 1% calf serum or both a competence and progression factor. (Fig. 1 A) . The positive control, in which a competence factor and progression factor were added to the fibroblast cultures, resulted in a large increase in fibroblast numbers within 3 d. Furthermore, IFNy in concentrations up to 1,000 U/ml was unable to augment or inhibit fibroblast replication in response to either mid-range or optimal concentrations of a competence factor (fibronectin) plus a progression factor (AMDGF) (Fig. 1 B) . IFNy was similarly inactive when FGF and insulin were the growth signals (data not shown).
Inhibition of lung fibroblast replication by PGE2. The addition of PGE2 to fibroblasts signaled to divide by both a competence and progression factor resulted in an inhibition of fibroblast replication (Fig. 2) . Nonreplicating fibroblasts cultured with optimal concentrations of fibronectin (2.0 ytg/ml) + AMDGF (10 ng/ml) increased in number by up to 112% within 3 d. (Fig. 3 A) . This increase in cell number was dependent on the concentration of IL-1, with 50% of the maximum increase observed at 6 to 10 U/ml (Fig. 3 B) . IL-I augmentation oflungfibroblast replication in response to both a competence and progression factor. In concert with its ability to increase the replication of lung fibroblasts signaled to divide by serum, IL-1 augmented cell replication when lung fibroblasts were signaled to divide by both a competence and progression factor in serum-free defined medium (Fig. 4) . Nonreplicating fibroblasts cultured with both a competence and progression factor (either fibronectin + AMDGF or FGF + insulin) demonstrated an increase in cell number within 2-3 d, and continued to divide for up to 5 d after the addition ofgrowth factors. The addition of IL-I to these cultures resulted in a consistent 10-15% augmentation of the growth observed with either fibronectin plus AMDGF (Fig. 4 A) , or FGF plus insulin (data not shown). The augmentation was IL-1 dose-dependent with 50% ofthe maximum response observed with 4-8 U/ml of IL-1 (Fig.   4 B) . Thus, IL-1 caused a modest but reproducible increase in fibroblast replication in defined medium above that observed in response to a competence plus progression factor. In view of the modest increment in cell number observed with the addition ofIL-1 compared with the substantial increase in cell number resulting from the primary growth signals, autoradiography was carried out to confirm these observations. While less than 6% of fibroblasts cultured in the absence of growth factors synthesized DNA within 24 h, the addition of either FGF plus insulin or fibronectin plus AMDGF resulted in 52-78% of the cells synthesizing DNA in the same time period. Consistent with the data from direct cell counts, the addition of IL-1 to the fibroblasts led to an increase in proliferation with nuclear labeling ranging from 59 to 89%. On the average, IL-I increased the numbers of labeled nuclei by 12±2% over that induced by fibronectin plus AMDGF alone. This augmentation was IL-1 dose dependent with 50% of the maximum effect observed at 5-10 U/ml (data not shown).
Assessment of the ability of IL-i to signal nonreplicating fibroblasts to divide. Although able to augment the replication of fibroblasts already signaled to divide, IL-1 was unable to provide either a competence or progression signal to nonreplicating fibroblasts (Fig. 5) . Nonreplicating fibroblasts cultured with IL-I and a known competence factor, either PDGF (0.5 U/ml), FGF (25 ng/ml), or fibronectin (1.0 gg/ml) did not increase in number compared with control fibroblasts cultured in media alone. As a positive control, a known progression factor (AMDGF, 5 ng/ml; or insulin, 25 gg/ml) resulted in a large (Fig. 6 ). When IL-I was added to fibroblasts cultured with fibronectin + AMDGF within 2 h of growth factor addition, the full augmentation of DNA synthesis (Fig. 6 A) and cell number (Fig. 6 B) indicated an effect early in the GI phase of the cell cycle. Therefore, early GI was examined in more detail using cells synchronized by mitotic detachment. Using this method, 80-88% of the cells were in M phase and entered GI within 2 h. The addition of IL-I any time after 6 h following entry into G1 resulted in no augmentation of fibroblast DNA synthesis. This confirmed that the effects of IL-1 were cell cycle-specific and occurred in early GI (data not shown).
Discussion
Tissue fibrosis, the replacement of normal parenchymal elements with increased numbers of fibroblasts and their connective tissue products, involves, in part, a complex interaction between mononuclear phagocytes and fibroblasts. In the fibrotic lung disorders, alveolar macrophages, the mononuclear phagocytes of the lung, spontaneously release or are able to release several molecules that are either known or putative modulators of lung fibroblast replication including fibronectin, AMDGF, IFN'y, PGE2, and IL-1. Evaluation ofeach ofthese mediators in defined medium indicated that the primary growth promoting signals for nonreplicating lung fibroblasts were fibronectin, which pro- IL-1 (units/ml) Fn and AMDGF. Experiments were carried out exactly as in Fig. 3 B except serum was omitted and replaced by Fn (1 ,ug/ml) + AMDGF (5 ng/ml). Cell counts were performed 5 d after growth factor addition. Shown for each concentration of IL-I is the percent increase in fibroblast number above that observed with Fn + AMDGF but without IL-1. 704 Bitterman et al. General concepts ofpulmonaryfibrosis Independent of cause, the fundamental anatomical feature of pulmonary fibrosis is an increased number of fibroblasts within the alveolar wall. Qualitative studies in humans (30, 31) , as well as morphometric studies in animals (10, 11, 32) , indicate a several-fold increase in fibroblast number in these disorders. As a result of this expansion of the lung fibroblast population, there tration is increased two-to fivefold (40) . One important source of fibronectin in the lower respiratory tract is the alveolar macrophage with a production that is increased up to 20-fold in the fibrotic lung disorders (5 (17) , and with the ability of IFNy to augment T lymphocyte replication apparently by inducing IL-2 receptor expression (28) as well as synovial cell and skin fibroblast replication in serum (41) . Therefore, although IFNy is released in increased amounts by mononuclear phagocytes from patients with at least one type of interstitial lung disorder (sarcoidosis) (15), it is unlikely to have a major direct effect on the evolution of the fibrotic process in the lung. PGE2. A cyclooxygenase metabolite of arachidonic acid, PGE2 is capable ofinhibiting lung fibroblast replication in defined medium in response to two of the important growth factors in the fibrotic lung disorders, fibronectin and AMDGF. This is consistent with the known observation that PGE2 inhibits the replication ofmesenchymal cells that have been signaled to divide by serum. For example, Ko et al. (19) have documented the ability of PGE2 to inhibit the replication of serum-stimulated dermal fibroblasts in a dose related manner. The potential relevance of PGE2 to lung fibroblast replication is suggested by direct estimates of PGE2 concentrations within the alveolar epithelial lining fluid. These measurements indicate values in the 10-20 ng/ml range in normal individuals (42), concentrations clearly capable of influencing fibroblast replication. However, consistent with it being an environment that promotes fibroblast replication, preliminary studies ofthe epithelial lining fluid concentration of PGE2 in patients with fibrotic lung disorders indicates values only 1/3 to '/2 of that in normals.
Mononuclear phagocytes from blood and lung, as well as from other sites, in both animals and human are able to produce PGE2, and when appropriately stimulated, can be induced to increase this production several-fold (43) (44) (45) (46) . In addition, mononuclear phagocytes from both lung (47, 48) and blood (49) release a macromolecule(s) capable ofinducing PGE2 production by fibroblasts, providing a possible mechanism for autocrine modulation of fibroblast replication.
IL-I. IL1, a 12,000 to 15,000-D mediator, is able to augment growth factor-induced lung fibroblast replication. Previous reports of the ability of ILi to stimulate fibroblast replication have emphasized the property of IL-1 as a co-stimulator, consistent with its role in thymocyte replication (50) . Schmidt et al. (6) demonstrated the ability of IL-to augment the replication of serum-stimulated, but not serum-free cultures of skin fibroblasts. Similarly, Estes and co-workers (22) found that IL-I could augment murine 3T3 cell replication in cultures containing optimal concentrations ofprogression factors only ifsmall to moderate amounts of PDGF (a competence factor) were present. In the absence of PDGF, no amount of IL-I was effective. These observations are consistent with the concept that IL-1 does not provide a primary (competence or progression) signal for cellular replication, but rather augments the ability of a target cell to respond to these signals.
To be effective, IL-1 was required during the early portion ofthe GI phase ofthe cell cycle, the interval when a competence signal is required for fibroblast replication. While I1-I is clearly incapable of providing a competence signal to either human lung fibroblasts or murine 3T3 cells, it is capable of increasing cellular replication in response to submaximal concentrations of a competence factor. There are two separate implications of this observation: (a) IL-l may be involved in some part, but not all, of the process of competence formation; and (b) scrupulous removal of all PDGF or other competence factors is required in any growth assay assessing the effects ofIL-I as a primary growth signal since small amounts of PDGF (or serum) in the culture system will result in fibroblast replication and the misinterpretation of IL-1 as a competence factor. The potential role of IL-1 in lung fibrosis remains undefined. Given its modest ability to augment fibroblast replication, IL-l likely has a relatively minor role in the fibrotic process in the lung. Consistent with this concept, in contrast to blood monocytes, alveolar macrophages have a limited ability to release IL-1 (21). However, in conditions such as sarcoidosis where the alveolar macrophage population is more "monocyte-like" (51), it is likely that IL-l may be more readily released by the alveolar macrophage population than in normal individuals (52) .
Therapeutic implications
The present study suggests at least two possible therapeutic approaches to the interruption of the fibrotic process in interstitial lung disorders: (a) inhibiting alveolar macrophage release of fibronectin and AMDGF and/or (b) increasing the PGE2 concentration in the alveolar epithelial lining fluid. In this regard, note that in idiopathic pulmonary fibrosis (a chronic progressive interstitial lung disorder), glucocorticoids, the mainstay oftherapy, result in long-term improvement in only a small proportion of patients. Consistent with this knowledge, corticosteroids fail to suppress fibronectin and AMDGF release (53) .
While there is no information on modulating lower respiratory tract PGE2 levels, preliminary studies in vitro suggest that modulating macrophage release offibronectin and AMDGF may be possible (54). In this context, colchicine in vitro leads to a dose related decrease in both fibronectin and AMDGF release by alveolar macrophages, suggesting a possible role in the treatment of patients with progressive pulmonary fibrosis. An understanding ofthe signals within the alveolar microenvironment that are relevant to fibroblast accumulation will, we hope, lead to other rational therapeutic modalities.
